Abstract
Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life and is perceived by patients as a major adverse effect of the treatment [1]. The use of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists plus dexamethasone has significantly improved the control of CINV [2]. Recent studies have demonstrated additional improvement in the control of CINV with the use of new agents: palonosetron, a second generation 5-HT3 receptor antagonist [3]; NK-1 receptor antagonists aprepitant, netupitant, and rolapitant [4–6]; and olanzapine, an antipsychotic which blocks multiple neurotransmitters in the central nervous system [7–9].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J (2006) Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472–4478
Navari RM (2013) Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents. Drugs 73:249–262
Navari RM (2013) The current status of the use of palonosetron. Expert Opin Pharmacother 14:1281–1284
Aapro M, Carides A, Rapoport BL (2015) Aprepitant and fosaprepitant: a ten-year review of efficacy and safety. Oncologist 20:450–458
Navari RM (2015) Profile of netupitant/palonosetron fixed dose combination (NEPA) and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Dev Ther 9:155–161
Navari RM (2015) Rolapitant for the treatment of chemotherapy induced nausea and vomiting. Expert Rev Anticancer Ther 15:1127–1133
Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9:188–195
Navari RM, Nagy CK, Gray SE (2013) Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:1655–1663
Tan L, Liu J, Liu X, Chen J, Yan Z, Yang H, Zhang D (2009) Clinical research of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 28:1–7
Navari RM (2012) Treatment of chemotherapy-induced nausea. Community Oncol 9:20–26
Stern RM, Koch KL, Andrews PLR (2011) Nausea: mechanisms and management. Oxford University Press, Oxford/New York
Fulton B, Goa KL (1997) Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 53:281–298
Kando JC, Shepski JC, Satterlee W, Patel JK, Rearns SG, Green AL (1997) Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia. Ann Pharmacother 31:1325–1334
Bymaster FP, Calligaro D, Falcone J, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87–96
Stephenson CME, Pilowsky LS (1999) Psychopharmacology of olanzapine: a review. Br J Psychiatry 174:52–58
Breithart W, Tremblay A, Gibson C (2002) An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics 43:175–182
Kim KS, Pae CU, Chae JH, Bahk WM, Jun T (2001) An open pilot trial of olanzapine for delirium for the Korean population. Psychiatry Clin Neurosci 55:515–519
Khojainova N, Santiago-Palma J, Kornick C, Breitbart W, Gonzales GR (2002) Olanzapine in the management of cancer pain. J Pain Symptom Manage 23:546–550
Bymaster FP, Falcone JF, Bauzon D, Kennedy JS, Schenck K, DeLapp NW, Cohen ML (2001) Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. Eur J Pharmacol 430:341–349
Rudd JA, Ngan MP, Wai MK, King AG, Witherington J, Andrews PL, Sanger GJ (2006) Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin. Neurosci Lett 392:79–83
Yakabi K, Sadakane C, Noguchi M, Ohno S, Shoki R, Chinen K, Aoyanna T, Sakurada T, Takabayashi H, Hattori T (2010) Reduced ghrelin secretion in the hypothalamus of rats due to cisplatin-induced anorexia. Endocrinology 151:3773–3782
Hurren KM, Berlie HD (2011) Lorcaserin: an investigational serotonin 2C agonist for weight loss. Am J Health Syst Pharm 68:2029–2037
Allison DB, Casey DE (2001) Antipsychotic-associated weight gain: a review of the literature. J Clin Psychiatry 62:22–31
Hale AS (1997) Olanzapine. Br J Hosp Med 58:443–445
Goldstein LE, Sporn J, Brown S, Kim H, Finkelstein J, Gaffey GK, Sachs G, Stern TA (1999) New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 40:438–443
Jackson WC, Tavernier L (2003) Olanzapine for intractable nausea in palliative care patients. J Palliat Med 6:251–255
Licup N, Baumrucker S (2010) Olanzapine for nausea and vomiting. Am J Hosp Palliat Care 27:432–434
Passik SD, Kirsh KL, Theobald DE, Dickerson P, Trowbridge R, Gray D, Beaver M, Comparet J, Brown J (2003) A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manage 25:485–489
Passik SD, Lundberg J, Kirsh KL, Theobald D, Donagby K, Holtschaw E, Cooper M, Dugan W (2002) Clinical note: a pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced pain and cancer. J Pain Symptom Manage 23:526–532
Pirl WF, Roth AJ (2000) Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report. Psychooncology 9:84–87
Srivastava M, Brito-Dellan N, Davis MP, Leach M, Lagman R (2003) Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manage 25:578–582
Lundberg JC, Passik S (2000) Controlling opioid-induced nausea with olanzapine. Prim Care Cancer 20:35–37
Passik S, Navari RM, Jung SH, Nagy CK, Vinson J, Kirsh KL, Loehrer PJ (2004) A phase I trial of olanzapine for the prevention of delayed emesis in cancer patients receiving chemotherapy. Cancer Invest 22:383–388
Navari RM, Einhorn LH, Passik SD, Loehrer PJ, Johnson C, Mayer ML, McClean J, Vinson J, Pletcher W (2005) A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 13:529–534
Navari RM, Einhorn LH, Loehrer PJ, Passik SD, Vinson J, McClean J, Chowhan N, Hanna NH, Johnson CS (2007) A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 15:1285–1291
Mizukami N, Yamanchi M, Koike K et al (2014) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. J Pain Symptom Manage 47:542–550
Navari RM, Qin R, Ruddy KJ et al (2015) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): alliance: A221301, a randomized, double-blind, placebo-controlled trial. ASCO palliative care symposium, abstract 176, Boston
Tina Shih YC, Xu Y, Elting LS (2007) Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer 110:678–685
Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano A, Morrow G, Oliver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21:232–243
Basch E, Prestrud AA, Hesketh PJ, Kris MG, Fever PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freunlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH (2011) Antiemetic American Society Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189–4198
Kris MC (2003) Why do we need another antiemetic? Just ask. J Clin Oncol 21:4077–4080
Navari RM (2007) Prevention of emesis from multiple-day chemotherapy regimens. J Natl Compr Canc Netw 5:51–59
Einhorn LH, Brames ML, Dreicer R, Nichols CR, Cullen MT, Bubalo J (2007) Palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 15:1293–1300
Albany C, Brames ML, Fausel C, Johnson CS, Picus J, Einhorn LH (2012) Randomized, double-blind, placebo-controlled, phase III crossover study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5-HT3 antagonist plus dexamethasone in patients with germ cell tumor receiving 5-day cisplatin combination chemotherapy regimens: a Hoosier Oncology Group (HOG) study. J Clin Oncol 30:3998–4003
NCCN Clinical Practice Guidelines in Oncology version 1 2015. Antiemesis. National Comprehensive Cancer Network (NCCN) [online]. Available from url: http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf. Accessed 30 Sept 2015
Generic cost of olanzapine. www.goodrx.com. Accessed Oct 2015
Editor, Wholesale cost of fosaprepitant (2015) Med Lett 57:60
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Navari, R.M. (2016). Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. In: Navari, R. (eds) Management of Chemotherapy-Induced Nausea and Vomiting. Adis, Cham. https://doi.org/10.1007/978-3-319-27016-6_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-27016-6_6
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-27014-2
Online ISBN: 978-3-319-27016-6
eBook Packages: MedicineMedicine (R0)